Por: MarketWatch Business April 26, 2023
Analysts had expected earnings of 33.28 pence on revenue of £6.49 billion, according to a FactSet poll. GSK is now a pure-play pharmaceutical company having shed its consumer-health division. It is currently in to bring the first vaccine for respiratory syncytial virus, or RSV, to market. RSV is a widespread virus that can cause serious illness, largely in children and older adults. Last month, the Food and Drug Administration’s advisory... + full article
Associated Press USA Health May 04, 2023
WASHINGTON (AP) — The U.S. approved the first vaccine for RSV on Wednesday, shots to protect older adults against a respiratory virus that’s most notorious for attacking babies but endangers their grandparents, too.The Food and Drug Administration decision makes GSK’s... + más
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
US approves 1st vaccine for RSV after decades of attempts | WPLG Local 10
New York Post USA Life May 04, 2023
The Food and Drug Administration on Wednesday approved Arexvy, the world’s first vaccine for RSV, or — a scientific breakthrough 60 years in the making. Manufactured by pharmaceutical giant GSK, the single-dose shot aims to prevent lower respiratory tract disease, caused by... + más
What Are the Duties of A Trustee? | Forbes
After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year | CNN
WPLG Local 10 USA Health May 03, 2023
WASHINGTON – The U.S. approved the first vaccine for RSV on Wednesday, shots to protect older adults against a respiratory virus that’s most notorious for attacking babies but endangers their grandparents, too.The Food and Drug Administration decision makes GSK’s shot,... + más
Strong RSV vaccine data lifts hopes after years of futility | WPLG Local 10
The Boston Globe USA Nation May 03, 2023
The Food and Drug Administration on Wednesday approved GSK’s vaccine for the respiratory syncytial virus, or RSV, for adults who are 60 and older, the company said.The vaccine, to be sold as Arexvy, appears to be the first in the world approved for sale to protect older adults... + más
Time USA Health March 03, 2023
GSK Plc’s vaccine for won the support of a key panel of U.S. regulatory advisers for use in people aged 60 and older, as the drugmaker races against Pfizer Inc. to bring to market the first vaccine for RSV. The panel of 12 outside advisers to the Food and Drug Administration... + más
FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks | CNBC
GSK vaccine for older adults granted FDA priority review | Fox Business
CNBC USA Health March 01, 2023
watch nowVIDEO1:5501:55FDA advisory panel votes in favor of adult RSV vaccine from GSK PLCThe Food and Drug Administration's independent panel of advisors on Wednesday recommended RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over... + más
FDA Panel Backs GSK’s RSV Vaccine for Older People | Time
Fox Business USA Business November 02, 2022
Check out what's clicking on FoxBusiness.com GSK opened 2% higher in U.S. trading Wednesday but closed down 2%. Shares rose after the drugmaker reported financial results that beat Wall Street forecasts and announced the Food and Drug Administration had accepted a biologics... + más
GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update | MarketWatch
About iurex | Privacy Policy | Disclaimer |